People channel feed

All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.

SIGN UP NOW
Subscribe to Endpoints News
John Maraganore (Scott Eisen/Bloomberg via Getty Images)

John Maraganore want­ed to be­come a biotech grand­dad af­ter leav­ing Al­ny­lam. With his new role at RTW, it looks like he got his wish

On his way out of Alnylam, outgoing CEO John Maraganore, who had led the biotech through thick and thin for 19 years, said late last year he wanted to advise new biotech companies in the grandfather phase of his career.

“It’s like a grandfather, right? You get the benefit of loving your grandchildren, but not having to take care of them all the time,” Maraganore said at the time. “I want to be a granddad.”

Tom Riga, Spectrum Pharmaceuticals CEO

Spec­trum hits the re­set but­ton, slic­ing away 30% of its work­force in piv­ot around 2 lead as­sets

Covid-19 has been a rough go for many drugmakers, but few more so than Spectrum Pharmaceuticals, which has seen inspection delays and unwanted CRLs haunt its chance at a first approval. Feeling the sting, Spectrum will now downsize to keep the lights on through the year.

Spectrum will cut 30% of its workforce and pivot its R&D efforts around its two furthest-along drugs as part of a restructuring effort that will pave the company’s cash runway out into next year, it announced Wednesday.

Jeff Albers and Kate Haviland (Brad Bahner Photography/PR Newswire)

Blue­print­'s long­time CEO pre­pares to step down as biotech rev­els in new Ay­vak­it launch, pipeline ex­pan­sion

After a busy 2021 brought Blueprint Medicines its fourth FDA approval, the company is kicking off the new year with plans to shake up its C-suite.

Jeff Albers, Blueprint’s CEO for the past eight years, will be stepping down April 4 and transitioning to the executive chairman position, the biotech announced Wednesday morning. He will be replaced by COO Kate Haviland, who moves into both the chief executive and president roles. Christina Rossi also nabs a promotion from chief commercial officer to COO.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 129,300+ biopharma pros reading Endpoints daily — and it's free.

Catalent CEO John Chiminski (Catalent)

Catal­ent CEO John Chimin­s­ki set to pass the torch this sum­mer af­ter 12 years at the helm

If there was one defining theme at Catalent in recent years, it was expansion, as the CDMO upped its operations all over the world, from Baltimore to Japan. It did so under longtime CEO John Chiminski, who has led the Somerset, NJ-based company for 12 years, topped by 2 years of the pandemic. This year will be the last in the C-suite for Chiminski, however, as the company announced plans for a passing of the torch this summer.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 129,300+ biopharma pros reading Endpoints daily — and it's free.

Third for­mer GSK sci­en­tist pleads guilty to con­spir­ing to steal trade se­crets

A third former GlaxoSmithKline scientist caught in an alleged plot to steal trade secrets and sell the work in China pleaded guilty to conspiracy on Monday.

Lucy Xi, a 44-year-old scientist, was accused of feeding her former husband, Yan Mei, confidential information on GSK’s research into monoclonal antibodies for his work on a new Chinese biotech company called Renopharma, according to the charges.

Elizabeth Holmes leaves federal court after the verdict in San Jose, CA, Jan. 3, 2022 (Nic Coury/AP Images)

Ther­a­nos founder Eliz­a­beth Holmes found guilty on four counts of de­fraud­ing in­vestors

The Theranos saga has captivated the pharma world over the last two decades, from its founding to its sharp rise and even sharper decline. And late Monday, its founder and former CEO Elizabeth Holmes was found guilty on several counts related to misleading investors, with each carrying a maximum of up to 20 years in prison.

Jurors returned the verdict Monday evening, finding Holmes guilty on one count of conspiracy to commit wire fraud and three counts of wire fraud against specific investors, with several news outlets reporting on the result. Holmes was found not guilty on four counts related to defrauding patients and jurors deadlocked on three counts of misleading individual investors.

Matthew Gantz, Castle Creek CEO

A Jeff Aronin start­up qui­et­ly yanks its IPO as the biotech mar­ket ends year on a whim­per

Close to 6 months after it initially posted its S-1 in what was still a thriving biotech IPO market, Castle Creek Biosciences has now yanked the offering as new deals fade against the background of a hard, year-end appraisal for drug stocks.

In its filing with the SEC, Castle Creek CEO Matthew Gantz merely states that the biotech is no longer pursuing an IPO. He had initially penciled in a $100 million raise last summer.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 129,300+ biopharma pros reading Endpoints daily — and it's free.

Bob Baloh, Novartis Head of Neuroscience at NIBR (via Cedars-Sinai)

No­var­tis taps Roche's neu­ro and rare dis­ease re­search lead to run neu­ro­science re­search

Even after agreeing to sell off $20 billion in shares back to Roche in November, Novartis got a bit more from its crosstown rival —  successfully getting ahold of Roche’s head of research for neuro and rare disease for themselves.

NIBR president Jay Bradner — a well-known name here at Endpoints — announced Bob Baloh’s appointment on Twitter. Baloh will be running NIBR’s neuroscience division.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 129,300+ biopharma pros reading Endpoints daily — and it's free.

Harvard University professor Charles Lieber leaves federal court, Tuesday, Dec. 14, 2021, in Boston (Michael Dwyer/AP Images)

'He re­peat­ed­ly lied': Feds pile on as Har­vard chemist Charles Lieber con­vict­ed of ly­ing about Chi­nese ties

In a stunning climax to an eye-catching saga, Harvard scientist Charles Lieber has been convicted of lying to the federal government about his ties to China’s Thousand Talents Program.

Following close to three hours of deliberation, a federal jury in Boston found 62-year-old Lieber — a pioneer in medical nanotechnology and the former chair of Harvard’s chemistry department — guilty of all six felony charges, including two counts of making false statements, two counts of filing false tax returns and two counts of failing to disclose a foreign (in this case Chinese) bank account.

DOJ charges for­mer Five Prime tri­al­ist with se­cu­ri­ties fraud af­ter $134K in in­sid­er trad­ing prof­its

The director of the gastrointestinal oncology program at the University of Chicago Medical Center has been charged by the US attorney in Chicago with insider trading after he made more than $134,000 from stock trades based on an early look at the results of a Five Prime Therapeutics trial.

The US attorney’s office said yesterday that back in early November 2020, Daniel Catenacci, a University of Chicago associate professor with more than a decade of experience who worked with Five Prime on early trials, purchased more than 8,700 shares of the company the morning before it announced positive results from a Phase II trial in treating advanced gastric/gastroesophageal cancer.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 129,300+ biopharma pros reading Endpoints daily — and it's free.